Sodium Bicarbonate
NaHCO₃ — sodium hydrogen carbonate
Indications for Sodium Bicarbonate
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Metabolic acidosis (severe renal disease, circulatory insufficiency, cardiac arrest, severe dehydration) | Adults & children | Adjunctive (IV) | FDA Approved |
| Urinary alkalinization | Adults & children | Monotherapy (oral or IV) | FDA Approved |
| Antacid (heartburn, dyspepsia) | Adults | Monotherapy (oral, OTC) | FDA Approved |
| Certain drug intoxications (barbiturates, salicylates, methanol) | Adults & children | Adjunctive (IV) | FDA Approved |
Sodium bicarbonate is among the most versatile medications in clinical practice. As the body’s primary physiological buffer, exogenous administration restores acid-base balance by consuming hydrogen ions and generating carbon dioxide for pulmonary excretion. Its clinical applications span emergency medicine, critical care, nephrology, and toxicology. While the injectable form is used for acute metabolic acidosis and cardiac arrest, oral formulations serve as both a prescription alkali supplement for chronic kidney disease-associated acidosis and an over-the-counter antacid.
Tricyclic antidepressant overdose / sodium channel blocker toxicity: IV sodium bicarbonate (1–2 mEq/kg bolus) is first-line therapy for QRS prolongation and cardiac toxicity from TCA poisoning. Endorsed by AHA/ACLS guidelines (Class IIb, LOE C). Also used for other sodium channel blocker toxicities (flecainide, cocaine, diphenhydramine). Evidence quality: Moderate (case series, expert consensus).
Hyperkalemia with metabolic acidosis (non-cardiac arrest): 50 mEq IV over 5 minutes as temporizing measure to shift potassium intracellularly. Most effective when concurrent acidosis is present. Evidence quality: Moderate.
CKD-associated chronic metabolic acidosis: Oral sodium bicarbonate (0.5–1.0 mEq/kg/day) to maintain serum bicarbonate ≥22 mEq/L. KDIGO 2012 and NKF-KDOQI recommend treatment when serum bicarbonate is persistently <22 mEq/L. May slow CKD progression. Evidence quality: Moderate (multiple RCTs; 2025 meta-analysis of 22 studies showed significant bicarbonate increase with favourable safety).
Contrast-induced nephropathy prevention: Evidence from meta-analyses remains inconclusive; sodium bicarbonate is not superior to normal saline hydration in most studies. Evidence quality: Low.
Dosing for Sodium Bicarbonate
Intravenous Dosing — Adult
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Cardiac arrest (ACLS) | 1 mEq/kg IV bolus | 50 mEq (50 mL of 8.4%) q5–10min, guided by ABG | Guided by ABG | Only after adequate ventilation established. Use 8.4% solution. Indicated for hyperkalemia or TCA OD-related arrest AHA 2020: routine use NOT recommended (Class III, LOE B) |
| Severe metabolic acidosis (pH ≤7.1–7.2) | 2–5 mEq/kg IV over 4–8 h | Guided by serial ABG | Target pH 7.30; avoid full correction in 24 h | Formula: HCO₃ deficit (mEq) = 0.5 × wt(kg) × (24 − serum HCO₃). Give half the calculated deficit, then reassess BICAR-ICU: benefit limited to AKI subgroup |
| Moderate metabolic acidosis | 50–150 mEq in 1 L D5W | Infuse at 1–1.5 L/h, then guided by ABG | Avoid overshoot alkalosis | Stepwise approach recommended; do not attempt full correction in first 24 h Target total CO₂ ~20 mEq/L by end of day 1 |
| TCA overdose / sodium channel blocker toxicity | 1–2 mEq/kg IV bolus | Repeat q15min until QRS <100 ms | Target pH 7.50–7.55 | Infusion: 150 mEq (3 amps) in 1 L D5W at 1.5–2× maintenance. Monitor ECG continuously First-line antidote for QRS prolongation >100 ms |
| Hyperkalemia with acidosis (non-arrest) | 50 mEq IV over 5 min | 150 mEq in 1 L D5W over 4 h | Guided by K+ and ABG | Most effective when concurrent acidosis present. Onset ~30 min; duration 1–2 h. Always combine with other K+-lowering measures Avoid in isolated hyperkalemia without acidosis (limited efficacy) |
| Urinary alkalinization (IV) — salicylate poisoning | 150 mEq (150 mL of 8.4%) in 1 L D5W | Titrate to urine pH 7.5–8.5 | Guided by urine pH | Add 20–40 mEq KCl per litre (hypokalemia impairs urinary alkalinization) Discontinue when salicylate <350 mg/L |
Oral Dosing — Adult
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| CKD-associated metabolic acidosis | 650 mg (7.7 mEq) TID | 325–2000 mg 1–4 times daily | Titrate to serum HCO₃ ≥22 mEq/L | Typical effective range: 0.5–1.0 mEq/kg/day. Monitor for fluid retention and hypertension KDIGO: treat when serum HCO₃ persistently <22 mEq/L |
| Urinary alkalinization (oral) | 3900 mg (loading dose) | 975–1950 mg q4h | Target urine pH 7.5–8.5 | Used for uric acid stone prevention, salicylate elimination, sulfonamide crystalluria prevention Adequate hydration essential |
| Antacid (OTC) | 650 mg q4h PRN | 650–2600 mg q4h PRN | Age <60: 15.6 g/day; Age ≥60: 7.8 g/day | Do not use for >2 weeks without physician oversight Dissolve in water before swallowing if applicable |
Pediatric IV Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Neonates / Infants <2 years — metabolic acidosis | 1–2 mEq/kg IV slow infusion | Guided by ABG | 8 mEq/kg/day | Use ONLY 4.2% solution (0.5 mEq/mL). Infuse slowly (not exceeding 1 mEq/kg/min). Hypertonic 8.4% is contraindicated in neonates Risk of intraventricular haemorrhage with rapid infusion or hypertonic solutions |
| Older children — metabolic acidosis | 2–5 mEq/kg IV over 4–8 h | Guided by ABG | Avoid full correction in 24 h | Same principles as adult dosing; serial monitoring essential Subsequent doses based on clinical response and ABG |
When calculating the bicarbonate deficit using the formula (0.5 × body weight × [24 − measured HCO₃]), it is safest to administer only half of the calculated deficit initially, then reassess with repeat arterial blood gas analysis. Attempting full correction within the first 24 hours risks overshoot metabolic alkalosis, which can be more dangerous than the acidosis itself — particularly in patients with compromised ventilation, where CO₂ accumulation can worsen intracellular acidosis paradoxically.
Pharmacology of Sodium Bicarbonate
Mechanism of Action
Sodium bicarbonate functions as the body’s principal extracellular buffer. When administered, the bicarbonate anion (HCO₃¯) directly consumes excess hydrogen ions (H+) to form carbonic acid (H₂CO₃), which is then rapidly converted by carbonic anhydrase to water and carbon dioxide. The CO₂ is eliminated through pulmonary ventilation, effectively removing the acid load. This reaction raises serum pH and replenishes the depleted bicarbonate buffer system. In TCA toxicity, sodium bicarbonate provides dual benefit: the sodium load overcomes sodium channel blockade to restore cardiac conduction, while the alkaline pH favours dissociation of the tricyclic drug from myocardial sodium channels. In hyperkalemia, the rise in extracellular pH drives potassium intracellularly via the H+/K+ exchange mechanism, transiently reducing serum potassium concentration.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | IV: 100% bioavailability (immediate). Oral: rapidly absorbed from GI tract; excess bicarbonate absorbed from small intestine. | IV onset is immediate for pH correction. Oral onset 15–30 min. Food does not significantly affect oral absorption. |
| Distribution | Distributed throughout extracellular fluid (ECF). Bicarbonate is an endogenous ion with normal serum concentration 22–28 mEq/L. | Volume of distribution approximates ECF volume (~0.3–0.5 L/kg). The 8.4% IV solution is profoundly hypertonic (~2000 mOsm/kg), which can shift fluid into the intravascular space. |
| Metabolism | HCO₃¯ + H+ → H₂CO₃ → CO₂ + H₂O (catalysed by carbonic anhydrase). No hepatic metabolism. | CO₂ must be exhaled — adequate ventilation is essential. In patients with inadequate ventilation, CO₂ accumulates and paradoxically worsens intracellular acidosis. |
| Elimination | Renal: bicarbonate is freely filtered at the glomerulus and ~85% is reabsorbed in the proximal tubule. Excess bicarbonate is excreted in urine (alkaline urine). Pulmonary: CO₂ exhaled. | In renal impairment, bicarbonate retention can cause sustained alkalosis and hypernatremia. In patients with intact renal function, excess bicarbonate is efficiently excreted. |
Side Effects of Sodium Bicarbonate
Sodium bicarbonate side effect frequencies are not well characterised in controlled trials because it is an endogenous electrolyte with decades of clinical use predating modern pharmacovigilance. The following frequency estimates are derived from clinical experience, FDA labelling, and published studies including the BICAR-ICU trials.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Hypernatremia | ≥10% (dose-dependent) | Each 50 mL of 8.4% solution delivers 50 mEq sodium. BICAR-ICU: hypernatremia significantly more common in bicarbonate group. Monitor serum sodium closely, especially with repeated boluses. |
| Metabolic alkalosis (overshoot) | ≥10% (with aggressive dosing) | BICAR-ICU: alkalosis observed more frequently in treatment group. Risk factors: rapid infusion, renal impairment, inadequate monitoring. Manifests as muscular twitching, irritability, tetany. |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Hypokalemia | ~5–10% (with alkalinization) | Alkalosis drives K+ intracellularly. Can precipitate arrhythmias, especially in patients on digoxin. Always check and correct K+ before or during bicarbonate therapy. |
| Hypocalcemia (ionized) | ~5% (BICAR-ICU data) | Rising pH increases calcium binding to albumin, reducing ionized calcium. Can cause tetany, perioral tingling, carpopedal spasm. Correct calcium before rapid bicarbonate infusion if baseline is low. |
| Fluid overload / Peripheral edema | ~3–8% | Hypertonic solution draws fluid intravascularly; sodium load exacerbates volume expansion. Higher risk in heart failure, cirrhosis, and renal failure patients. |
| GI effects (oral): bloating, flatulence, belching | ~5–15% | CO₂ generation in stomach causes gastric distension. May reduce appetite in chronic oral use. Taking with food may worsen symptoms. |
| Nausea (oral) | ~2–5% | More common with higher oral doses. May reduce adherence in chronic CKD use. |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Paradoxical intracellular acidosis | Uncommon | Minutes post-bolus if ventilation inadequate | Ensure adequate ventilation before and during administration. CO₂ freely crosses cell membranes while HCO₃¯ does not, worsening intracellular pH if CO₂ cannot be exhaled. |
| Extravasation injury (tissue necrosis) | Rare | During or shortly after peripheral IV infusion | Stop infusion immediately. Hypertonic, alkaline solution causes chemical cellulitis, ulceration, and sloughing. Preferably administer via central line for concentrated solutions. |
| Pulmonary edema | Rare | Hours; rapid bolus dosing | Higher risk in neonates and elderly. Reduce rate and volume. Treat with diuretics and respiratory support as needed. |
| Cerebral haemorrhage (neonates) | Rare | During rapid infusion of hypertonic solution | Use only 4.2% solution in neonates; administer slowly (≤10 mEq/min). Rapid osmolality shifts can cause intraventricular haemorrhage in premature infants. |
| Severe metabolic alkalosis (pH >7.55) | Uncommon | Hours to days with overcorrection | Discontinue bicarbonate. May require IV normal saline, potassium chloride, or rarely dilute HCl infusion. Can cause seizures, arrhythmias, and reduced oxygen delivery. |
For patients on chronic oral sodium bicarbonate for CKD-associated acidosis, GI bloating is the most common reason for non-adherence. Strategies include dividing the daily dose into smaller, more frequent doses, taking tablets with meals, using sodium citrate solution (Shohl’s solution) as an alternative alkali source, or considering enteric-coated preparations where available.
Drug Interactions with Sodium Bicarbonate
Sodium bicarbonate interacts with other drugs through two primary mechanisms: alteration of gastric and urinary pH (affecting oral drug absorption and renal clearance), and direct physicochemical incompatibility in IV solutions. Unlike most drugs, sodium bicarbonate does not interact via CYP enzymes since it is not hepatically metabolised.
Monitoring for Sodium Bicarbonate
-
Arterial Blood Gas
Before, during, and after IV therapy; q1–2h in acute settings
Routine Primary monitoring parameter for IV sodium bicarbonate. Target pH depends on clinical scenario: cardiac arrest (restore pH), metabolic acidosis (target ~7.30), TCA OD (target pH 7.50–7.55). Avoid overshoot alkalosis. -
Serum Bicarbonate / Total CO₂
Baseline, q4–8h (acute); q1–3 months (chronic oral)
Routine For chronic CKD use, target serum bicarbonate ≥22 mEq/L (KDIGO). Do not attempt to normalise entirely during the first 24 h of acute IV therapy. -
Serum Potassium
Before and during therapy; q2–4h acutely
Routine Alkalinization shifts K+ intracellularly; can unmask or worsen hypokalemia. Particularly dangerous in patients on digoxin. Correct K+ concurrently. -
Serum Sodium
Baseline, then q4–8h during IV therapy
Routine 8.4% solution delivers 1 mEq Na+ per mL. Hypernatremia is a common complication with repeated boluses. Target Na+ <150 mEq/L. -
Ionized Calcium
Before therapy if baseline calcium low; during rapid alkalinization
Trigger-based Rising pH reduces ionized calcium. Pre-existing hypocalcemia must be corrected before alkalinization to prevent tetany and arrhythmia. -
Urine pH
Q1–2h during urinary alkalinization
Trigger-based Target 7.5–8.5 for salicylate poisoning. Hypokalemia impairs the ability to alkalinize urine; correct potassium concurrently. -
Fluid Balance & Blood Pressure
Continuous during IV; each clinic visit for chronic oral
Routine Sodium load causes fluid retention. Monitor weight, peripheral edema, and blood pressure. Particular caution in heart failure and CKD patients. Chronic oral bicarbonate may worsen hypertension.
Contraindications & Cautions for Sodium Bicarbonate
Absolute Contraindications
- Pre-existing metabolic or respiratory alkalosis: Administration will worsen alkalosis and its complications (arrhythmias, seizures, impaired oxygen delivery).
- Hypochloremia: When alkalosis is secondary to chloride depletion, saline replacement — not bicarbonate — is the appropriate treatment.
- Known loss of sodium bicarbonate from GI or urinary tract (volume ≥1500 mL/day) — treat the underlying cause rather than replacing bicarbonate empirically.
Relative Contraindications (Specialist Input Recommended)
- Decompensated heart failure: High sodium load may precipitate pulmonary edema and worsen volume overload. If bicarbonate therapy is essential, use with diuretic cover and close haemodynamic monitoring.
- Severe renal impairment (eGFR <15 mL/min) without dialysis access: Impaired bicarbonate and sodium excretion increases risk of metabolic alkalosis, hypernatremia, and fluid overload.
- Hypernatremia (Na+ >150 mEq/L): Sodium bicarbonate will worsen hypernatremia. Correct sodium before initiating bicarbonate therapy.
- Hypocalcemia: Alkalinization reduces ionized calcium further; correct calcium before rapid bicarbonate administration.
Use with Caution
- Diabetic ketoacidosis (DKA): Sodium bicarbonate is not routinely recommended in DKA since insulin therapy corrects ketoacid production. The ADA recommends considering bicarbonate only if pH <6.9–7.0. Risks include paradoxical CNS acidosis and worsening hypokalemia.
- Lactic acidosis: Most experts recommend sodium bicarbonate only when pH <7.1 and tissue perfusion and ventilation are maximised. BICAR-ICU showed benefit limited to AKI subgroup.
- Neonates: Use only 4.2% concentration; administer slowly. Hypertonic solutions carry risk of intraventricular haemorrhage.
- Elderly patients: Greater frequency of decreased renal function; start at lower doses and monitor closely. Patients ≥60 using oral bicarbonate as antacid should not exceed 7.8 g/day.
- Patients on corticosteroids or diuretics: Enhanced potassium loss may precipitate severe hypokalemia during concurrent bicarbonate therapy.
The FDA label warns that overly aggressive therapy with sodium bicarbonate injection can result in metabolic alkalosis (associated with muscular twitchings, irritability, and tetany) and hypernatremia. In less urgent forms of acidosis, do not attempt full correction within the first 24 hours; a gradual rise to a total CO₂ content of approximately 20 mEq/L by the end of the first day is the recommended target. Rapid correction may be accompanied by an unrecognised alkalosis because of the delay in readjustment of ventilation to normal.
Patient Counselling for Sodium Bicarbonate
Purpose of Therapy
Sodium bicarbonate is prescribed to correct or prevent excess acid in the blood (metabolic acidosis), which can occur in kidney disease, certain poisonings, or during critical illness. In kidney disease, long-term oral sodium bicarbonate helps protect kidney function and maintain the body’s acid-base balance. As an over-the-counter antacid, it provides short-term relief from heartburn and indigestion.
How to Take (Oral)
Oral sodium bicarbonate tablets are typically taken several times daily with a full glass of water. Some formulations should be dissolved in water before swallowing. Take at least 1–2 hours away from other medications to avoid interactions. For antacid use, do not take for more than 2 weeks without medical advice. For chronic kidney disease, take as prescribed even if you feel well.
Sources
- Sodium Bicarbonate Injection, USP (8.4%). Full prescribing information. Hospira/Pfizer. Pfizer Medical Primary reference for IV dosing, cardiac arrest protocol, metabolic acidosis treatment, and adverse reactions.
- Sodium Bicarbonate. In: StatPearls. National Library of Medicine; Updated 2024. StatPearls Comprehensive clinical review covering all indications, mechanisms, dosing protocols, and contraindications for both IV and oral sodium bicarbonate.
- Jaber S, Paugam C, Futier E, et al. Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet. 2018;392(10141):31–40. doi:10.1016/S0140-6736(18)31080-8 Landmark ICU trial (n=389): no overall mortality benefit, but significant reduction in mortality and need for RRT in the AKI subgroup (AKIN 2–3).
- Jung B, Jabaudon M, De Jong A, et al. Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury: The BICARICU-2 Randomized Clinical Trial. JAMA. 2025;334(22):2000–2010. doi:10.1001/jama.2025.20231 Follow-up trial (n=627): no reduction in 90-day mortality, but 15% absolute reduction in need for renal replacement therapy (35% vs 50%).
- Kraut JA, Madias NE. Treatment of acute metabolic acidosis: a pathophysiologic approach. Nat Rev Nephrol. 2012;8(10):589–601. doi:10.1038/nrneph.2012.186 Authoritative pathophysiological review of acid-base correction strategies including formula-based bicarbonate dosing and stepwise approach to therapy.
- Merchant RM, Topjian AA, Panchal AR, et al. Part 1: Executive Summary: 2020 American Heart Association Guidelines for CPR and Emergency Cardiovascular Care. Circulation. 2020;142(16 Suppl 2):S337–S357. doi:10.1161/CIR.0000000000000918 Current AHA ACLS guidelines: sodium bicarbonate not recommended routinely in cardiac arrest (Class III, LOE B); recommended for hyperkalemia and TCA overdose (Class IIb, LOE C).
- Kidney Disease: Improving Global Outcomes (KDIGO) 2012 Clinical Practice Guideline for the Evaluation and Management of CKD. Kidney Int Suppl. 2013;3(1):1–150. doi:10.1038/kisup.2012.73 Recommends oral alkali therapy when serum bicarbonate is persistently below 22 mEq/L in CKD patients.
- Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335–1343. doi:10.2337/dc09-9032 ADA consensus on DKA management: sodium bicarbonate considered only if pH <6.9–7.0 after initial fluid resuscitation.
- Bruccoleri RE, Burns MM. A Literature Review of the Use of Sodium Bicarbonate for the Treatment of QRS Widening. J Med Toxicol. 2016;12(1):121–129. doi:10.1007/s13181-015-0483-y Comprehensive review of sodium bicarbonate as antidote for sodium channel blockade including TCA, cocaine, flecainide, and diphenhydramine toxicity.
- Alshahrani MS, McConachie I. Use of Sodium Bicarbonate in Cardiac Arrest: Current Guidelines and Literature Review. J Clin Med Res. 2016;8(4):277–283. PMC4780490 Review of 25 years of evidence regarding sodium bicarbonate in cardiac arrest, supporting current restrictive AHA recommendations.
- Raphael KL. Approach to the Treatment of Chronic Metabolic Acidosis in CKD. Am J Kidney Dis. 2016;67(4):696–702. doi:10.1053/j.ajkd.2015.12.021 Expert review of oral alkali dosing strategies, available formulations, and monitoring in chronic CKD metabolic acidosis management.
- Raphael KL, Isakova T, Engberding N, et al. Effects of Oral Sodium Bicarbonate in Patients with CKD. Clin J Am Soc Nephrol. 2013;8(5):714–720. doi:10.2215/CJN.08340812 Dose-response pilot study (n=20) demonstrating dose-dependent serum bicarbonate increase and improved lower extremity muscle strength in CKD patients with mild acidosis.
- Siddiqui AH, Batool F, Khan S, et al. Safety and efficacy of sodium bicarbonate for treating metabolic acidosis in chronic kidney disease: A systematic review and meta-analysis. World J Nephrol. 2025;14(1):101078. WJN Meta-analysis of 22 studies (n=2932): sodium bicarbonate significantly increased serum bicarbonate (MD: 2.59 mEq/L) with favourable safety profile in CKD.